A Study on the Preference of Risperidone Dosage Forms
Launched by SHANGHAI MENTAL HEALTH CENTER · Oct 23, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how patients with certain mental health conditions, like schizophrenia, bipolar disorder, autism spectrum disorder, and others, prefer to take their medication. Specifically, the study is focused on different forms of the medication risperidone, which is an antipsychotic used to help manage symptoms in these conditions. The goal is to understand what dosage forms (like tablets, liquids, or injections) patients find easiest and most comfortable to use.
To be eligible for this study, participants must be either patients diagnosed with one of these conditions or their primary caregivers who agree to take part. However, individuals who have trouble reading and understanding Chinese or choose not to participate will not be included. If you join the study, you can expect to share your opinions and experiences regarding the different ways of taking risperidone. This information will help researchers improve treatment options for people with these mental health conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with schizophrenia, bipolar disorder, autism spectrum disorder, mental retardation or their primary caregivers who voluntarily participate in the study.
- Exclusion Criteria:
- • Have difficulty reading and understanding Chinese or refuse to participate in the study.
About Shanghai Mental Health Center
Shanghai Mental Health Center is a leading institution dedicated to advancing mental health research and treatment. As a prominent clinical trial sponsor, the center focuses on innovative therapeutic approaches and evidence-based practices to address a wide range of psychiatric disorders. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to enhancing patient care through rigorous clinical trials that contribute to the understanding and management of mental health conditions. Its mission is to foster collaboration among researchers, clinicians, and patients to promote mental well-being and improve outcomes in mental health care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported